Loading...
Loading...
Gilead Sciences, Inc. GILD reported significantly softer sales of its blockbuster Hep C drug, Sovaldi. Gilead reported that sales were down almost 20 percent on a quarter-over-quarter basis.
Analysts were expecting some softening in revenues, but the company's numbers came in below Wall Street's $2.97 billion sales expectation. Gilead booked sales of $2.8 billion for the period -- a decline of nearly 6 percent.
In after-hours trading, Gilead's stock price is down 2.86 percent to $100.25 per share.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in